• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Tolerogenic dendritic cells as a therapy for treating lupus
【24h】

Tolerogenic dendritic cells as a therapy for treating lupus

机译：致耐受性树突状细胞作为治疗狼疮的疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that is characterized by the over production of auto-antibodies against nuclear components. Thus, SLE patients have increased morbidity and, mortality compared to healthy individuals. Available therapies are not curative and are associated with unwanted adverse effects. During the last few years, important advances in immunology research have provided rheumatologists with new tools for designing novel therapies for treating autoimmunity. However, the complex nature of SLE has played a conflicting role, hindering breakthroughs in therapeutic development. Nonetheless, new advances about SLE pathogenesis could open a fruitful line of research. Dendritic cells (DCs) have been established as essential players in the mechanisms underlying SLE, making them attractive therapeutic targets for fine-tuning the immune system. In this review, we discuss the recent advances made in revealing the mechanisms of SLE pathogenesis, with a focus on the use of DCs as a target for therapy development.
机译：系统性红斑狼疮（SLE）是一种慢性自身免疫性疾病，其特征是针对核成分的自身抗体生产过多。因此，与健康个体相比，SLE患者的发病率和死亡率增加。可用的疗法无法治愈，并且会带来不良的不良反应。在过去的几年中，免疫学研究的重要进展为风湿病学家提供了用于设计治疗自身免疫的新疗法的新工具。但是，SLE的复杂性起了冲突的作用，阻碍了治疗发展的突破。尽管如此，关于SLE发病机制的新进展可能会开辟一个富有成果的研究领域。树突状细胞（DC）已被确立为SLE潜在机制中的重要角色，使其成为微调免疫系统的有吸引力的治疗靶标。在这篇综述中，我们讨论了揭示SLE发病机理的最新进展，重点是使用DC作为治疗发展的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号